Dabur India seems to have found itself entangled in a major controversy surrounding a ‘misleading’ advertisement over its product – Chyawanprash.
Dabur one of the biggest Ayurvedic companies in India also sells Chaywanprash.
They recently published an advertisement in several newspapers to claim that Chyawanprash could protect against COVID-19.
Dabur made this statement with a claim that it had conducted a clinical trial research study of the formula that supported the statement.
Independent Fact Checker – Alt News “looked at Dabur’s claim and the general efficacy of Chyawanprash in preventing COVID-19 and found no scientific evidence in the form of published peer reviewed articles”.
Claims:
- Dabur claims that regular consumption of their Chyawanprash reduced the risk of COVID-19 by up to 12 times.
- Chyawanprash consumption can prevent COVID-19.
Fact Check:
Alt News did a keyword search for Chyawanprash and Chyavanprash and found 10 clinical studies registered with CTRI.
All these studies are trying to test if Chyawanprash consumption can prevent COVID-19.
“We did a keyword search for “Dabur Chyawanprash Clinical study on COVID-19” on Google Scholar and PubMed database of scientific publications and found no results.
“Similarly, there were no preprints of the study on both BioRxiv and MedRxiv preprint servers.
“This means that there is no research paper published by Dabur to back their claim,” Alt News claimed.
“The results listed on their website are suspicious,” added Alt News.
“In Dabur’s case, there is no evidence at all. Dabur has not published any papers on either of the clinical trials they did on Chyawanprash. Hence the claim on their website and newspaper advertisement is misleading,” said Alt News.